PHARMACOKINETICS OF SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 ADMINISTRATION IN CANCER-PATIENTS

被引：0
作者：
CARUSO, B
GIAVARINA, D
JIRILLO, A
GIAVARINA, M
BALLI, M
机构：
[1] LEGNAGO HOSP,CLIN CHEM LAB,VERONA,ITALY
[2] LEGNAGO HOSP,DEPT RADIOTHERAPY & ONCOL,VERONA,ITALY
来源：
EOS-RIVISTA DI IMMUNOLOGIA ED IMMUNOFARMACOLOGIA | 1992年 / 12卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Data from a clinical trial with recombinant Interleukin (rIL-2) subcutaneousy administered are here reported. Five patients with cancer were administered with r-IL2. Serum levels were measured on serial samples by immunoenzymatic method. This method is easier than biological methods, allowing to measure rIL-2 only as antigen. Therefore, immunoenzymatic method can be on support in the comprehensive study of IL-2 farmacokynetic. rIL-2 was detectable in serum in all the patient treated, with different levels and time.
引用
收藏
页码：207 / 209
页数：3
相关论文
共 50 条
  • [41] PHARMACOKINETICS AND TISSUE DISTRIBUTION OF HUMAN RECOMBINANT INTERLEUKIN-2 IN MICE
    TANG, ZM
    LIU, XW
    XU, LP
    SHAN, CW
    SONG, QS
    [J]. ACTA PHARMACOLOGICA SINICA, 1994, 15 (01): : 51 - 56
  • [42] REPORT OF ROCHE RECOMBINANT HUMAN INTERLEUKIN-2 (RO-23-6019) CLINICAL-TRIALS IN CANCER-PATIENTS
    ITRI, LM
    [J]. JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1987, 6 (02): : 219 - 220
  • [43] REVERSIBLE ANERGY IN CIRCULATING LYMPHOCYTES OF CANCER-PATIENTS DURING INTERLEUKIN-2 THERAPY
    CLEMENTI, E
    BUCCI, E
    CITTERIO, G
    LANDONIO, G
    CONSOGNO, G
    FORTIS, C
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1994, 39 (03) : 167 - 171
  • [44] PRODUCTION OF AND RESPONSE TO INTERLEUKIN-2 IN PERIPHERAL-BLOOD LYMPHOCYTES OF CANCER-PATIENTS
    WANEBO, HJ
    PACE, R
    HARGETT, S
    KATZ, D
    SANDO, J
    [J]. CANCER, 1986, 57 (03) : 656 - 662
  • [45] RECOMBINANT INTERLEUKIN-2
    BRUTON, JK
    KOELLER, JM
    [J]. PHARMACOTHERAPY, 1994, 14 (06): : 635 - 656
  • [46] Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs
    Chen, SA
    Sawchuk, RJ
    Brundage, RC
    Horvath, C
    Mendenhall, HV
    Gunther, RA
    Braeckman, RA
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2000, 293 (01) : 248 - 259
  • [47] INVITRO ANTITUMOR-ACTIVITY OF EOSINOPHILS FROM CANCER-PATIENTS TREATED WITH SUBCUTANEOUS ADMINISTRATION OF INTERLEUKIN .2. ROLE OF INTERLEUKIN-5
    RIVOLTINI, L
    VIGGIANO, V
    SPINAZZE, S
    SANTORO, A
    COLOMBO, MP
    TAKATSU, K
    PARMIANI, G
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1993, 54 (01) : 8 - 15
  • [48] NATURAL-KILLER (NK) CELLS AND RECOMBINANT INTERLEUKIN-2 (RIL-2) ACTIVATED KILLER (LAK) CELLS IN CANCER-PATIENTS
    CHING, N
    KUBOTA, I
    LOPEZ, M
    ANCHETA, A
    WONG, GK
    CHING, C
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 1987, 42 (04) : 380 - 380
  • [49] RENAL IMPAIRMENT ASSOCIATED WITH THE PREOPERATIVE ADMINISTRATION OF RECOMBINANT INTERLEUKIN-2
    DEEHAN, DJ
    HEYS, SD
    BROOM, J
    EREMIN, O
    WHITING, PH
    [J]. CLINICAL SCIENCE, 1994, 87 (05) : 513 - 518
  • [50] EFFECTS OF SUBCUTANEOUS RECOMBINANT IL-2 ON HUMORAL IMMUNITY IN ADVANCED CANCER-PATIENTS
    CASAMASSIMA, A
    GUIDA, M
    LATORRE, A
    ABBATE, I
    TRIANTAFILLOU, V
    MUSCI, M
    DELENA, M
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 1993, 3 (02) : 171 - 176
12345